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ABSTRACT: Different prokineticin receptor antagonists, based on the 
triazinedione scaffold, were synthesized by a new efficient method. Here we 
demonstrated that 5-benzyltriazinedionessubstituted in position para of the 
benzyl group with halogens provide compounds endowed with interesting 
selectivity for the Prokineticin receptor 1 (PKR1). BRET technology indicates 
that such substitutionresults in increased affinity for thePKR1.The affinity for 
PKR2, always in M range, was never significantly affected by the para-
halogen-benzyl pharmacophores. The analog bearing a para-bromobenzyl 
pharmacophore (PC-25) displayed the highest affinity for PKR1 (~18 times 
higher than the reference PC-1 that bears apara-ethyl benzyl group) and the 
highest selectivity (~300 times). The other halogen substitutedanalogs (PC-7, 
PC-18 and PC-35), showed selectivity for PKR1 more than 100 times higher than 
for PKR2. Using transgenic mice lacking one of the two PKRs we demonstrated 
that all these compounds were able to abolish the Bv8-induced hyperalgesia in 
mice still expressing the PKR1 at doses lower than those necessary to abolish 
hyperalgesia in mice expressing only the PKR2. The dose ratio reflected the in- 
vitro evaluated receptor selectivity. 
INTRODUCTION: The prokineticins (among 
them the mammalian molecules named 
Prokineticin 1, PROK1, prokineticin 2, PROK2, 
and their Amphibian homologous, Bv8) make up a 
new family of chemokines 
1, 2
 which, in mammals, 
activate two G-protein linked receptors 
(prokineticin receptor 1 and 2, PKR1 and PKR2).  
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Intensive research of the prokineticin system over 
thepast decade has revealed a dazzling array of 
physiological functions 
3
. In addition, the 
disruption of prokineticin system has been 
implicated in several pathological conditions, 
including cancer 
4
, immunological response 
5, 6
 and 
persistent pain 
3
. 
 
In animal models of inflammatory 
7
 and 
neuropathic 
8
 pain, in which the prokineticin 
system is highly activated, we already 
demonstrated that the prokineticin receptor 
antagonist PC-1 
9
 not only abolishes pain, 
hindering the nociceptor sensitization, but also 
reduces the over expression of the endogenous 
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mediator, the PROK2 
10
. By using mice lacking the 
prokr1 or the prokr2 gene we demonstrated that the 
up-regulation of PROK2 as well as its 
proinflammatory and immunomodulatory effects 
are both mediated by the receptor PKR1
7, 6, 11
. 
 
Our purpose is to find out molecules endowed with 
higher affinity and/or selectivity for the PKR1. We 
foresee that these molecules might be novel drugs 
effective in controlling development of immuno-
inflammatory processes which underlay several 
pathological conditions.  
 
In previous papers we described the synthesis of a 
series of prokineticin-receptor antagonistsendowed 
with PKR1 selectivity 
12
. In in- vivo screening we 
demonstrated that molecules containing a fluorine 
atom in para position of the benzyl pharmacophore, 
were effective in abolishing the Bv8-induced 
hyperalgesia at very low doses (fmol ranges). 
 
Considering this behaviour it could be interesting 
to prepare and evaluate the affinity and selectivity 
of the other four halogen substituted PC1-analogs 
in -vitro, using the BRET technology, and in- vivo, 
testing the compounds in transgenic mice 
expressing only one of the PKRs i.e. mice lacking 
the prokr1 or the prokr2 gene. 
 
In both experimental setting we evaluated the 
ability of the new compounds to quench the effects 
of Bv8. Bv8 is the Amphibian homologue of 
PROK2 which, like PROK2, displays no selectivity 
for either receptors, but about 10 times higher 
affinity, and we demonstrated to be a very good 
pharmacological tool to mimic the activity of the 
endogenous agonist PROK2 
13
. 
 
MATERIALS AND METHODS: 
In- vitro experiments 
cDNA Constructs and preparation of cell lines To 
prepare cDNA constructs expressing prokineticin 
receptors fused to the N-terminus of Renilla 
Luciferase (Rluc), PCR fragments coding for the 
PROKR1 and PROKR2 sequences were inserted 
into pRluc-C vectors (Packard), upstream of the 
Rluc-coding sequence. Each receptor-Rluc 
chimeric sequence was then transferred into a 
pQCIXN retroviral vector (Clontech) expressing 
the neomycin resistance gene. The preparation of 
bovine Gβ1 tagged at the N-terminal with RGFP 
(Renilla green fluorescent protein, Prolume) was 
described in Molinari et al.
14
 
 
SH-SY5Y human neuroblastoma cells were grown 
in a 1:1 mixture of Dulbecco’s modified Eagle’s 
medium and F-12 supplemented with 10% (v/v) 
foetal bovine serum in a humidified atmosphere of 
5% CO2 at 37 °C. Cell lines stably co-expressing 
each luminescent receptor (PKR1-Rluc, PKR2-
Rluc) in association with RGFP-Gβ1 were obtained 
by infecting cells sequentially with retroviruses 
encoding the fusion proteins, followed by selection 
with G418 ( 500µg/ml) in combination with 
Hygromicin B (100μg/ml). The expression level of 
chimaeric proteins was determined by measuring 
the intrinsic luminescence and fluorescence of cell-
membrane preparations 
14
.  
 
BRET (Bioluminescence Resonance Energy 
Transfer) assays. The use of Renilla photoproteins 
as reporters of protein–protein interactions has been 
described previously 
14
. G-protein-coupling assays 
were performed in membranes (prepared by 
differential centrifugation as described 
15
) from 
neuroblastoma SHSY5Y cells expressing 
luminescent PKR1 or PKR2 and fluorescent G1. 
Membranes (5 mg of proteins) were incubated in 
sterile 96-well white plastic plates (Packard View 
Plate) containing 2–5 µM coelenterazine (Prolume) 
and different concentrations of Bv8 (10
-12 
- 10
-6
 M) 
in PBS for 10 min. Luminescence was recorded 
sequentially using two band pass filters (blue, 
450/20 nm, and green, 510/20 nm, 3rd Millenium, 
Omega Optical, VT) in a plate luminometer 
(VICTOR light, PerkinElmer). To measure the 
effect of PKR antagonists onBv8-induced receptor-
G protein coupling, concentration-response curves 
of antagonists were generated in the presence of 5 
nM Bv8. 
 
Data analysis: RET ratios were calculated as the 
ratios of high energy (donor) and low energy 
(acceptor) emissions sequentially recorded through 
the 450 nm and 510 nm filters corrected for 
spectral overlap, i.e.,  
RET ratio = (CPS 510× T450/ CPS 450× T510) − 1, 
where CPS indicates photon counts per second and 
T is the relative transmittance of the filters, as 
reported by the manufacturer. 
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In -vivo experiments 
Animals 
Male C57Bl6 PKR1(-/-) or PKR2(-/-) mice 
(Lexicon Genetics, The Woodlands, TX) weighing 
25-30 g were used for behavioral experiments. 
Mice were housed in plastic cages (5 for each 
group) and maintained under 12:12 light-dark cycle 
at 21 ± 1 °C and 50 ± 5% humidity with food and 
water ad libitum. All animal experiments were 
conducted under protocols approved by the Animal 
Care and Use Committee of the Italian Ministry of 
Health. Animal care was in compliance with the 
IASP and European Community 
(E.C.L.358/118/12/86) guidelines on the use and 
protection of animals in experimental research. All 
efforts were made to minimize animal suffering 
and to reduce the number of animal used. 
 
Measurement of nociceptive threshold  
The nociceptive threshold to thermal stimuli was 
evaluated by the Paw-Immersion test. 
 
This test was performed by dipping one mouse 
hind-paw into hot water (48°C) and measuring the 
latencies to paw withdrawal. For measurement of 
the nociceptive threshold, mice were trained in paw 
withdrawal test during the week preceding the 
experiment. This adaptation protocol reduced 
variability in threshold measurements, giving a 
more stable baseline and making drug-induced 
changes easier to detect. On the day of the 
experiment, nociceptive threshold was measured 
for 2 h at 30 min intervals before drug injection. 
The mean of the last three of these threshold 
measurements were taken as baseline nociceptive 
threshold (NTB). Nociceptive threshold was then 
determined three times at 15, 30, 60, 90, 120, 150, 
180 min after saline or drug administration. The 
mean of the three readings at each time point was 
defined as the nociceptive threshold at that time in 
the presence of the test solution (NTTS). The effect 
of the tested drug was calculated as the percentage 
change in nociceptive threshold from baseline 
threshold (%∆NT) according to the following 
equation: %∆NT = 100 x (NTTS – NTB)/ NTB 
 
Drug injections 
Bv8 was extracted from the skin secretion of the 
frog Bombina variegata and purified to 98% 
(HPLC), as previously described 
16
. Bv8 was 
dissolved in saline and injected in a volume of 20 l 
into one hind paw (intraplantar, i.pl.) of mice at the 
dose of 630 f mol .The antagonists were dissolved 
in a saline and injected in a volume of 20l, i.pl., in 
the same paw, 5 min before Bv8. After drugs 
administration the animals were observed for three 
hours at the established time intervals. For each 
drug dose, a different group of 5 male mice from 
each genotype was used. 
 
Statistical analysis 
The data are presented as mean ± S.E. mean values. 
Statistical analyses were performed using two-way 
ANOVA followed by Bonferroni post test. * P < 
0.05 ** P<0.01 *** P < 0.001. 
 
Molecular Modelling 
Homology modelling 
Modeller v9.13 was used to build homology 
models of human Prokinetic in receptors PKR1 and 
PKR2 (Uniprot codes Q8TCW9 and Q8NFJ6 
respectively) using the crystal structures of human 
kappa opioid (PDB code 4DJH) and neurotensin 1 
(PDB code 4GRV) receptors as templates. The 
highly conserved N
1.50
 in TM 1, D
2.50
 in TM 2, R
3.50
 
in TM 3, W
4.50
 in TM 4, P
5.50
 in TM 5, P
6.50
 in 
TM6, and P
7.50
 in TM 7, which define the 
Ballesteros and Weinstein numbering scheme, were 
used as reference points in TM sequence 
alignments.  
 
Docking of Prokineticin receptor antagonists 
All docking calculations were performed using 
Discovery Studio. The Flexible docking protocol 
was used, assigning side chains to selected residues 
of the orthosteric binding site using ChiFlex. The 
ligand docking algorithm was LibDock, and the 
refinement of the selected protein side-chains in the 
presence of the rigid ligand was made with 
ChiRotor. The docked poses were evaluated with 
the CDOCKER scoring function.  
 
RESULTS AND DISCUSSION: 
In vitro assay 
In BRET assay the Bv8-induced interaction 
between PKR1 or PKR2 and the  subunit of 
heterotrimeric G-proteins resulted in a dose-
dependent enhancement of RET signal (Fig. 1A, 
B). Bv8-association curves with the PKR1 (EC50 = 
4.9 nM) and the PKR2 (EC50 = 2.9 nM) were 
similar, confirming that Bv8, like the mammalian 
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ligand PROK2, binds PKR1 and PKR2 with the 
same affinity, hence is a good ligand to generate 
displacement curves from PKR1- and PKR2-
preparations directly comparable. PC-1 dose-
dependently reduced the Bv8-induced RET signal 
and displayed 20 times higher affinity for PKR1 
(IC50 = 144 nM) than for PKR2 (IC50 =2964 nM) 
(Fig. 1C, D) confirming the binding results 
measured as competition for 
125
I MIT binding 
9
. 
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FIGURE 1: Concentration-response curves for Bv8-induced enhancement of RET ratio in membranes prepared fromSHSY5Y 
cells co-expressing fluorescent G and luminescent PKR1 (A) or PKR2 (B). EC50 values are 4.9 ± 0.5 nM and 2.9 ± 0.3 nM for 
PKR1 and PKR2, respectively. Concentration-dependent inhibition of 5 nM Bv8-induced-RET by PC-1 in PKR1 (C) or PKR2 
(D) cell membranes. IC50 values are 144 ± 15 nM and 2964 ± 215 nM for PKR1 and PKR2, respectively. Data points are means 
± S.E.M. of three experiments. 
PC-7 (Fig. 2A) resulted about 100 times more 
selective for PKR1 (IC50 = 36 nM) than for PKR2 
(IC50 = 4400 nM) and displayed 4 times higher 
affinity for PKR1 than the lead compound PC-1.  
Again 
125
I MIT-binding assay (not shown) gave 
affinity values for PKR1 (IC50 = 50 nM) and PKR2 
(IC50 = 5700 nM) comparable to those obtained 
with BRET assay.  
 
PC-18 and PC-35 (Fig 2 C, D), bearing a para-
iodine and para-chlorine, behaved very similar to 
PC-7: they maintain the same low affinity for PKR2 
and a comparable affinity for PKR1. 
PC-25 displayed the highest affinity for PKR1 (~18 
times higher than PC-1) and the highest selectivity 
for PKR1 (~300 times) (Fig. 2B and Table1).  
These data clearly indicate that para-halogen 
substitution of the benzyl group in the 5-position of 
triazinedione scaffold significantly increased the 
affinity for the PKR1, while it did not affected the 
affinity for the PKR2.  The compounds containing 
the otherhalogens, chlorine, iodine and fluorine 
(compd. PC-18, PC-35 and PC-7, respectively) 
showed about 5 times lower affinity than the best 
compound PC-25, containing bromine. 
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FIGURE 2: CONCENTRATION-DEPENDENT INHIBITION OF Bv8 (5nM)-INDUCED RET SIGNAL IN PKR1 (￭) OR PKR2 (▼) 
CONTAINING CELL MEMBRANES BY HALOGENATED PC-1-ANALOGS. REPRESENTATIVE CURVES OF THREE 
SEPARATE EXPERIMENTS.  
IC50 values for PKR1 and PKR2 are reported in Table 1. 
TABLE 1. AFFINITY AND SELECTIVITY OF THE HALOGENATED PCS EXPRESSED AS IC50 VALUES. DATA ARE MEANS 
± S.E.M. OF THREE EXPERIMENTS 
Triazinediones PKR1 IC50 (nM) PKR2 IC50 (nM) 
Selectivity 
(IC50 PKR2 / IC50 PKR1) 
N
N
N
O
O N
H
H
N
Et
MeO
NH
NH2
 
PC-1 
(reference) 
144 ± 15 2964 ± 215 20.6 
N
N
N
O
O N
H
H
N
F
MeO
NH
NH2
 
PC-7 
36 ± 6.1 4399 ± 340 122 
N
N
N
O
O N
H
H
N
Cl
MeO
NH
NH2
 
PC-18 
28 ± 3.2 4400 ± 310 157 
N
N
N
O
O N
H
H
N
Br
MeO
NH
NH2
 
PC-25 
8 ± 0.5 2162 ± 180 270 
N
N
N
O
O N
H
H
N
I
MeO
NH
NH2
 
PC-35 
39 ± 4.9 4440 ± 385 114 
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In- vivo assay 
In PKR1(-/-) and PKR2(-/-) mice i.pl. injection of 
Bv8 (5 ng = 630 fmol) induced comparable 
hyperalgesia evaluated as decrease of the 
nociceptive threshold to thermal stimuli. 
Hyperalgesia was already evident in 15 min, 
peaked in 60 min and lasted for about 3 h. Pre-
injection (-5 min) of the compounds, into the paw, 
antagonized the Bv8-induced hyperalgesia in dose-
dependent manner. In PKR1(-/-) mice a dose of 150 
pmol of PC-1 abolished thermal hyperalgesia 
induced by Bv8, whereas in PKR2(-/-) mice a 10 
folds lower dose (15 pmol) of PC-1 was enough to 
obtain the same effect (Fig.3). 
 
Evaluation of the dose-effect relationship was 
obtained considering the area under the curves 
(AUC) for each tested dose. This analysis 
confirmed that the antihyperalgesic effect of PC-1 
is more than 10 times higher in PKR2(-/-) mice 
respect to PKR1(-/-) mice accordingly with its 
preferential affinity for PKR1, the receptor still 
present in PKR2(-/-) mice (Fig. 3). 
FIGURE 3: EFFECTS OF INTRAPLANTAR (i.pl.) PRE-INJECTION (-5 min) OF VARIOUS DOSES OF PC-1 ON THERMAL 
HYPERALGESIA INDUCED BY Bv8 (5 ng, i.pl.) IN PKR2(-/-) AND PKR1(-/-) MICE. THE ANTIHYPERALGESIC EFFECT WAS 
EVALUATED AS AUC OF THE TIME-RESPONSE CURVE FOR EACH DOSE. 
As demonstrated in Fig.4, PC-7 and PC-25 
antagonized the Bv8-induced thermal hyperalgesia 
in PKR1-KO mice at doses of 15 pmol and 14 
pmol, but in PKR2-KO mice at doses of 0.15 pmol 
and 0.04 pmol, respectively, confirming a 
selectivity of 100 and 300 times for PKR1. 
PC-18 and PC-35 appeared less effective than PC-
7, being necessary significantly higher doses to 
counteract the Bv8 induced hyperalgesia, however 
the ratio of the effective doses in PKR1 (-/-) and 
PKR2 (-/-) mice was consistent with their 
selectivity: about 100 folds. 
 
FIGURE 4: DOSE-DEPENDENT INHIBITION OF Bv8-INDUCED HYPERALGESIA BY PRETREATMENT WITH VARIOUS 
DOSES OF PC-7, PC-18, PC-25 AND PC-35 IN PKR2(-/-) AND PKR1(-/-) MICE. THE ANTIHYPERALGESIC EFFECT OF 
VARIOUS DOSES OF THE HALOGENATED COMPOUNDS WAS EVALUATED AS AREA UNDER THE TIME-RESPONSE 
CURVE (AUC). 
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Molecular Modelling 
Using a flexible docking method (see Materials and 
Methods), the known antagonist PC-1 was docked 
to the binding site of the structural model of the 
PKR1 receptor. Residue side chains that were 
considered flexible were E2.61, R3.32, T4.64, Qi+2 
(at position i+2, relative to the conserved C180i 
engaged in a disulfide bond with C3.25 in TM 3), 
R6.58 and E7.39. The highest scored poses were 
ranked and inspected visually, to determine 
whether they satisfy the experimental results. 
Based on the docking results, as seen in Fig. 5A, 
the guanidine group interacts with E2.61 and F7.35, 
while one of the carbonyl oxygens interacts with 
R6.58. The anisole oxygen forms a hydrogen bond 
with N3.29 and the ethyl benzene groups is located 
in hydrophobic vicinity formed by T4.64 and 
F4.63. The interactions with PKR2 are similar, with 
the difference of the A4.64 instead of the threonine 
(Fig. 5B). In the case of PC-25, the bromine of the 
benzene group is interacting with the T6.46 
hydroxyl group of PKR1 through a halogen bond 
(Fig. 5C see Conclusion), whereas the absence of 
this interaction can be seen on Fig. 5D. 
 
FIGURE 5. DOCKING MODELS OF PC-1 AND PC-25. DIFFERENCES IN THE BINDING OF PC-1 (CYAN STICKS) 
INTERACTING WITH THE BINDING SITE RESIDUES OF PKR1 (PANEL A) AND PKR2 (PANEL B). DIFFERENCES IN THE 
BINDING OF PC-25 (CYAN STICKS) INTERACTING WITH THE BINDING SITE RESIDUES OF PKR1 (PANEL C) AND PKR2 
(PANEL D). THE COLOUR CODE OF THE HELICES IS TM 2 IN YELLOW, 3 IN RED, 4 IN GRAY, 6 IN BLUE, AND 7 IN 
LIGHT BROWN, WHERE EL2 IS IN GREEN 
CONCLUSIONS: The primary structures of PKR1 
and PKR2 are highly homologous, having a 
sequence identity of 91% and BLOSUM62 
similarity of 96%. All residues that are located in 
the different binding pockets (mayor and minor 
binding pocket as well as the extracellular entrance, 
the latter often involved in allosteric modulation of 
class A GPCR) are fully conserved with the 
exception of position 4.64 in which PKR2 has an 
alanine (A201 in absolute numeration) instead of a  
threonine (T192), featured in PKR1. Most sequence 
variation between the PKR subtypes is 
concentrated in the extracellular N terminal region, 
which contains a nine-residue insert in PKR1 
compared with PKR2, as well as in the second 
intracellular loop (ICL2) and in the C terminal tail. 
A conserved disulfide bridge connects the second 
extracellular loop (ECL2) with the extracellular end 
of TM3 a characteristic shared with more than 80% 
of class A GPCR. Levitet al.
17
, analyzing the 
Lattanzi et al, IJPSR, 2014; Vol. 5(11): 5064-5072.                                       E-ISSN: 0975-8232; P-ISSN: 2320-5148 
International Journal of Pharmaceutical Sciences and Research                                                                              5071 
human PKRs, identified a putative extracellular 
surface binding site, which most likely binds the 
endogenous PKR ligands, but also confirmed PKRs 
are able to use a pocket located in the upper part of 
the TM bundle among TMs 3,4,5,6, and 7, the 
extracellular entrance, were synthetic small-
molecule supposedly bind. 
 
In- vitro experiments using BRET technology 
confirmed results we previously obtained for PC-1 
and PC-7, from competitive binding experiments 
labelling the PKRs with 
125
I MIT 
9
. 
 
Our docking models show residues at position 4.64 
(T192 in PKR1 and A201 in PKR2, the only non-
conserved residue of the binding sites between 
PKR1 and PKR2), are responsible of the selectivity 
of PC-1 towards PKR1. T4.64 (T192) in PKR1 
potentially stabilizes the ethyl benzene group by 
offering an extra methyl group, enhancing the 
hydrophobic of this region. All the compounds 
containing a halogen atom instead of the ethyl 
group in para-position of the benzyl 
pharmacophore of the 5-position of the 
triazinedione scaffold resulted more selective and 
displayed higher affinity for PKR1.  
 
Interestingly, PC-25, which contains a bromine 
atom displayed the highest affinity for PKR1 (~18 
times higher than PC-1) and the highest selectivity 
(~300 times). Despite the fact PC-35, containing 
iodine, has not the highest affinity, the observed 
trend in binding is likely ascribable to the 
formation of a halogen bond. Halogen bond, is a 
specific semi-directional molecular interaction 
between a halogen atom, acting as a Lewis acid, 
and an electron-rich partner (O, N, or S acting as 
Lewis basis) and which strength follow the size of 
the positively charged -hole on the tips of the 
atoms, thus I>Br>Cl>F. 
 
They are abundant in biological systems
18
 and 
database surveys reveal that halogen bonding is the 
prevalent interaction between halogenated ligand 
and target protein 
19, 20
. Moreover around 25% of 
the “top 200 brand name drugs by retail dollar in 
2009” possess halogen atoms in their molecular 
structures 
21
. Therefore, halogens have a key role in 
drug development. The trend in affinity of 
halogenated compounds to PKR1 follow the 
halogen bond trend, I>Br>Cl>F with the exception 
of iodine, while no clear trend is observed in the 
affinity to PKR2, as expected since it misses a 
Lewis base in position 4.64. Following and 
confirming the docking of PC-1, compounds PC-7, 
PC-18, PC-25 and P-35, are likely forming halogen 
bonds with the hydroxyl group of T4.64 (Fig. 5C) 
explaining both the higher affinity of these 
compounds to PKR1 as well as their selectivity.  
 
Despite their affinity trend is clearly following the 
halogen bond strength trend, no statistically 
difference is observed in the binding of PC-7, PC-
18 and PC-35. Wilcken et al.
21
, in an analysis of 
the halogen bonds found in PDB and involving 
threonines, observed that most of the -I···O- 
distances are of in the range of 5.50-6Å, while most 
of the Cl···O was of around 3.5Å.  
 
The calculated distances between the halogens of 
PC-7, PC-18, PC-25 and P-35 and the oxygen of 
T4.64 are of 3.0Å±0.2, which perfectly fits with 
many of the observed 
21 
halogen bonds between Br-
containing compounds and threonines, thus 
explaining why PC-25 is statistically binding 
stronger PKR1 than PC-7, PC-18 and PC-35. 
Moreover the iodine of PC-35 is likely too close to 
the oxygen of T4.64 thus limiting the quality of its 
halogen bond.  
 
In-vivo all these compounds were able to 
antagonize dose-dependently the hyperalgesia 
induced by the i.pl. injection of 5 ng Bv8. In 
PKR1(-/-) mice, in which only the receptor-2 is still 
present, higher doses were necessary than in 
PKR2(-/-) mice which still express the receptor-1. 
The dose ratio well mirrored the selectivity for the 
PKR1.  Hence this in vivo test performed on mice 
expressing only one of two PKRs is a quick and 
reliable method to evaluate antagonists of the 
prokineticin system. 
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